APBN New Site

APBN Developing Site

Overcoming Chemotherapy Resistance in Ovarian Cancer

An international research team, led by scientists from Mater Research – The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

Within in the team Principal Investigator, Professor John Hooper and his team based at the Translational Research Institute (TRI) in Brisbane, Australia, collaborated with researchers from the Queensland University of Technology (QUT) and the Mayo Clinic in the United States of America.

The study was published in the scientific journal, Cancers, it provides the rationale for a clinical trial to evaluate the use of low-dose 2-deoxy-D-glucose in treating patients with clear cell ovarian cancer.

In a pre-clinical study, the team found that 2-deoxy-D-glucose, could be used at very low levels to significantly improve the effectiveness of the chemotherapy drug carboplatin to treat laboratory models of clear cell ovarian cancer.

“Ovarian clear cell carcinoma is associated with poor prognosis and resistance to chemotherapy,” Prof Hooper said.

“The key finding from our study is that low levels of 2-deoxy-D-glucose markedly improved the efficacy of carboplatin against preclinical models of this ovarian cancer. Our pre-clinical work used cells taken from patient tumours, so we were very encouraged that we could use such a low dose of 2-deoxy-D-glucose to overcome resistance to chemotherapy in this cancer and stop tumour growth.”

“This drug has been trialled previously in other cancers, but we were able to use a 10-fold lower dose than previously reported so that it’s safer for patients and is less likely to cause side-effects.” He added.

Following the announcement that the research team has received an award to progress the ovarian cancer research, they are hoping to being trialling the treatment combination in patients within the next 12 months.

The Judith Meschke Memorial Grant was presented by the peak, national gynaecological cancer clinical trials organization for Australia and New Zealand (ANZGOG). This funding will allow the researchers to study adjustments of metabolism to improve the effectiveness of chemotherapy for clear cell ovarian cancer.

Professor Hooper gratefully acknowledged the generosity of the ANZGOG funding from a bequest of Judith Meschke.

“The involvement in the project of so many talented people, scientists and clinicians, is in the spirit of the creative process fostered by the diverse and talented Australian arts community exemplified by the achievements of Ms Meschke,” he said. [APBN]